192 related articles for article (PubMed ID: 24137041)
1. A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS).
Pan H; Xie F; Liu P; Xia J; Ji Y
Clin Trials; 2014 Feb; 11(1):49-59. PubMed ID: 24137041
[TBL] [Abstract][Full Text] [Related]
2. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
Xie F; Ji Y; Tremmel L
Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
[TBL] [Abstract][Full Text] [Related]
3. A novel Bayesian seamless phase I/II design.
Pan H; Huang P; Wang Z; Wang L; Li C; Xia J
PLoS One; 2013; 8(9):e73060. PubMed ID: 24023809
[TBL] [Abstract][Full Text] [Related]
4. Sequential or combined designs for Phase I/II clinical trials? A simulation study.
Rossoni C; Bardet A; Geoerger B; Paoletti X
Clin Trials; 2019 Dec; 16(6):635-644. PubMed ID: 31538815
[TBL] [Abstract][Full Text] [Related]
5. Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design.
Yan D; Wages NA; Dressler EV
J Biopharm Stat; 2019; 29(2):333-347. PubMed ID: 30451068
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
Koopmeiners JS; Modiano J
Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
[TBL] [Abstract][Full Text] [Related]
7. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
Yada S; Hamada C
Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
[TBL] [Abstract][Full Text] [Related]
8. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
9. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.
Ji Y; Wang SJ
J Clin Oncol; 2013 May; 31(14):1785-91. PubMed ID: 23569307
[TBL] [Abstract][Full Text] [Related]
10. A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts.
Guo B; Yuan Y
Stat Med; 2015 May; 34(10):1721-32. PubMed ID: 25626676
[TBL] [Abstract][Full Text] [Related]
11. Randomized dose-escalation designs for drug combination cancer trials with immunotherapy.
Mozgunov P; Jaki T; Paoletti X
J Biopharm Stat; 2019; 29(2):359-377. PubMed ID: 30352007
[TBL] [Abstract][Full Text] [Related]
12. SPIRIT: A seamless phase I/II randomized design for immunotherapy trials.
Guo B; Li D; Yuan Y
Pharm Stat; 2018 Sep; 17(5):527-540. PubMed ID: 29882388
[TBL] [Abstract][Full Text] [Related]
13. A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations.
Jiménez JL; Kim S; Tighiouart M
Biom J; 2020 Sep; 62(5):1300-1314. PubMed ID: 32150296
[TBL] [Abstract][Full Text] [Related]
14. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials.
Shi H; Cao J; Yuan Y; Lin R
Stat Med; 2021 May; 40(11):2626-2649. PubMed ID: 33650708
[TBL] [Abstract][Full Text] [Related]
15. A bivariate Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis.
Thygesen H; Dragalin V; Whitehead A; Whitehead J
Pharm Stat; 2012; 11(6):476-84. PubMed ID: 23011957
[TBL] [Abstract][Full Text] [Related]
16. Dose-finding design driven by efficacy in onco-hematology phase I/II trials.
Seegers V; Chevret S; Resche-Rigon M
Stat Med; 2011 Jun; 30(13):1574-83. PubMed ID: 21394754
[TBL] [Abstract][Full Text] [Related]
17. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
Trials; 2014 Feb; 15():68. PubMed ID: 24571662
[TBL] [Abstract][Full Text] [Related]
18. Sequential monitoring of Phase I dose expansion cohorts.
Iasonos A; O'Quigley J
Stat Med; 2017 Jan; 36(2):204-214. PubMed ID: 26854196
[TBL] [Abstract][Full Text] [Related]
19. Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.
Wages NA; Tait C
J Biopharm Stat; 2015; 25(5):903-20. PubMed ID: 24904956
[TBL] [Abstract][Full Text] [Related]
20. Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents.
Hoering A; Mitchell A; LeBlanc M; Crowley J
Clin Trials; 2013; 10(3):422-9. PubMed ID: 23529697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]